CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Correctly Ranks Therapy that Led to Extraordinary Response in Metastatic Breast Cancer Patient

CureMatch Correctly Ranks Therapy that Led to Extraordinary Response in Metastatic Breast Cancer Patient
Case Studies

In this case study, a retrospective analysis was performed using data from a metastatic breast cancer patient. The patient was given five lines of treatment; the first four quickly failed and the fifth was highly successful. The analysis shows that CureMatch can correctly rank the efficacy of treatment options, and illustrates multiple benefits of using the CureMatch analysis.

Case Study
A 38-year old woman was diagnosed with breast cancer in August 2009. The histologic diagnosis was invasive ductal adenocarcinoma, expressing estrogen receptor (ER) and progesterone receptor (PR). The initial tumor had already spread and metastatic liver disease was observed on CT scans.

Soon after diagnosis, the patient received her first line of chemotherapy, consisting of paclitaxel. The treatment was stopped after 3 months, due to lack of efficacy. Additional lines of treatment included chemotherapy (fluorouracil/doxorubicin/cyclophosphamide), a single-agent hormone therapy (tamoxifen), and additional chemotherapy (capecitabine). None of these therapies helped to reduce the size of the tumor, and progression of the disease was observed in less than 3 months with each of them.

After the fourth relapse, that patient’s physician decided to perform DNA-sequencing on the primary breast tumor sample, to seek personalized therapy options. Next-generation DNA sequencing was performed by Foundation Medicine (FoundationOne® – 315 gene panel). The analysis revealed pathogenic alterations within CCND1, FGFR1 and PRKDC genes. Additional protein analysis revealed a loss of the PTEN protein. Following these molecular profile insights, her physician prescribed personalized combination therapy: anastrozole (hormone therapy) in combination with everolimus (targeting the CCND1 and PTEN alterations).

Rapidly following the combination therapy, the size of the liver metastases decreased by 56%, and the patient was considered to be in partial response, which has continued for at least 11 months after treatment initiation.

Fig. 1. CT scans of the abdomen before treatment (left) and after 6 months of treatment (right). After 6 months the patient exhibited a partial response (56% decrease in hepatic disease).

 

Retrospective Analysis
The CureMatch analysis was retrospectively performed to determine whether CureMatch would have been effective in correctly ranking therapy options, using published patient data. A score distribution from the resulting CureMatch report is shown in Fig. 2, which ranks the likely efficacy of various treatment options using combinations of 1, 2, or 3 drugs. The efficacy of the options is ranked by descending Strength Score, which is a proprietary scoring system developed by CureMatch that analyzes the individual patient’s molecular tumor profile and estimates the best therapeutic agents using proprietary algorithms and manually-curated databases.

Case Study 4

FIg. 2. Score Distribution from CureMatch report. All possible combinations of 1, 2, or 3 drugs are represented and ordered by descending strength score. The successful therapy is shown in green, the unsuccessful lines of treatment in red, and other potential options (that could have also been considered) in blue.

In the CureMatch report, the successful personalized combination therapy option (anastrozole + everolimus) received a Strength Score of 42, whereas all of the unsuccessful chemotherapy and hormone therapy options (shown in red) had scores below 20. Other potential therapy options that were suggested by CureMatch as options, but not considered for the patient during treatment, are also shown in the plot in blue.

The conclusions are two-fold:

  1. If the patient had received DNA sequencing and the CureMatch analysis immediately following the initial diagnosis, four unnecessary lines of treatment (chemotherapy and hormone therapy) may have been avoided, likely reducing the following:
    • Exposure to unnecessary chemicals and their toxicities
    • Wasted time, during which there was further spread of the disease
    • Cost of unnecessary treatments
    • Drug resistance resulting from unnecessary/unsuitable treatments, which may affect the efficacy of subsequent treatments
    • Negative impacts to the emotional health and quality of life of the patient
  2. An even more effective therapy could have been chosen. Note that in Fig. 2, the selected therapy had a Strength Score of 42.  However, if the CureMatch analysis had been available, at least nine even higher-ranked options could have also been considered (shown in blue to the left of the selected option), including four options with scores above 50.

This case study further supports the notion that personalized combination therapy should be considered early in the treatment process. CureMatch empowers oncologists with the knowledge and insight to consider these options for their patients.

The original study was published by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and her colleagues in the journal BMC Cancer. Co-authors on the article were J.J. Wheler, J.T. Atkins, F. Janku, S.L. Moulder, R. Yelensky, P.J. Stephens, and Razelle Kurzrock. The subsequent retrospective analysis was performed by CureMatch.

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data